日本語⁄English
2019.06.04
【NanoCarrier Co.,Ltd.】「Press release by VBL Therapeutics on “VBL Final Phase 1/2 Study Results Presented at ASCO Demonstrate VB-111 Dose Dependent Increase in Overall Survival and 58% CA-125 Response Rate in Platinum-Resistant Ovarian Cancer”」
